| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable |
|
Medicine details |
|
| Medicine name | daratumumab (Darzalex®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 3045 |
| Indication | In combination with bortezomib, thalidomide and dexamethasone for adults with newly diagnosed multiple myeloma who are suitable for stem cell transplant. |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/07/2020 |
| NICE guidance | |